Spear Bio to Unveil Novel Alzheimer’s Disease Immunoassays and Fully Automated Instrument Platform at AAIC 2026
Launches include the first commercially available singleplex eMTBR-Tau immunoassay, a novel pTau 217 assay for venous and capillary blood, and a fully automated instrument platform
Spear Bio, an innovator in ultrasensitive protein biomarker detection, today announced plans to unveil new SPEAR immunoassay and instrument innovations at the Alzheimer’s Association International Conference® 2026, taking place July 12–15 in London, UK.
The launches include the first commercially available singleplex immunoassay for eMTBR-Tau, a novel epTau 217 assay for measuring pTau 217 across venous and capillary blood, and an instrument platform to fully automate SPEAR workflows. Together, these innovations expand Spear Bio’s Alzheimer’s disease and neurodegenerative biomarker portfolio, giving scientists new tools to investigate both amyloid-associated tau phosphorylation and tau tangle pathology from ultra-low sample volumes.
Designed as a standalone singleplex assay, the SPEAR eMTBR-Tau immunoassay provides researchers a focused and quantitative approach to measuring tau tangle-associated biology while maintaining the ultra-low sample volume and simplified workflow advantages of SPEAR technology. SPEAR epTau 217 complements this approach by enabling consistent pTau 217 measurement across venous and capillary blood, supporting broader investigation of amyloid-associated tau phosphorylation in Alzheimer’s disease research.
